South Korean AI-based pharma firm Oncocross secures $14m Series B

South Korean AI-based pharma firm Oncocross secures $14m Series B

Source: Laurynas Mereckas/Unsplash

South Korean drug developer Oncocross has raised 16.5 billion won ($14 million) in a Series B funding round led by Smilegate Investment and GNTech Venture Capital.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter